145. Antimicrobials are Associated with Adverse Cardiac Events Post AMI
Session: Poster Abstract Session: Antimicrobial Stewardship: Adverse Drug Events
Thursday, October 8, 2015
Room: Poster Hall
  • ABX and Cardiac Event IDweek poster2.pdf (326.8 kB)
  • Background: In some studies antimicrobials (especially macrolides) have been associated with negative cardiac outcomes in healthy populations.  Thus, we investigated adverse cardiac-related events in a population of Medicare beneficiaries with an acute myocardial infarction (AMI) within the previous year to estimate the risk of these antimicrobial agents in a high risk population.  

    Methods: We constructed a cohort of 185,010 Medicare beneficiaries diagnosed with an AMI.  We followed the patients for one year after their index AMI.  For each week a patient was followed, we determined whether a patient suffered another AMI, an arrhythmia or any important cardiac event.  Also, in each week, we determined if a prescription was filled for any of the following antimicrobials:  azithromycin, levofloxacin, clarithromycin, amoxicillin, amoxicillin-clavulanate, doxycycline or moxifloxacin.  For each of the 3 cardiac outcomes and 7 antimicrobials, we created a logistic regression model with robust standard errors. The main independent variable was antimicrobial prescription in a week, and the dependent variable was a cardiac event in the following week. Each of the 21 models included patients’ comorbidities, medications, procedures, demographics, and insurance status.

    Results: For 20 models, an antimicrobial prescribed in the previous week was positively associated with the cardiac events studied. Only doxycycline was not associated with AMI . Estimated odds ratios, from smallest to largest, were doxycycline (1.37 to 1.68), amoxicillin (1.72 to 2.34), azithromycin (1.72 to 2.34), amoxicillin-clavulanate (2.23 to 2.34), moxifloxacin (2.50 to 2.78), clarithromycin (3.16 to 3.70) and levofloxacin (2.99 to 2.36). 

    Conclusion: We found that all 7 antimicrobials were positively associated with adverse cardiac events. However, the elevated risk for non-macrolide and non-fluoroquinolone agents suggests that some of this cardiac risk may be due to the condition for which the antimicrobial agent is being prescribed. Thus, further work is needed to determine if antimicrobials themselves or the conditions they were meant to treat are the cause of these adverse events.

    Linnea Polgreen, PhD, Pharmacy Practice & Science, University of Iowa, College of Pharmacy, Iowa City, IA, Benjamin Riedle, MS, Pharmacy Practice and Science, University of Iowa, Iowa City, IA, Joseph Cavanaugh, PhD, Biostatistics, University of Iowa, College of Public Health, Iowa City, IA, Mary Schroeder, PhD, Division of Health Services Research, Department of Pharmacy Practice and Science, University of Iowa, College of Pharmacy, Iowa City, IA and Philip M. Polgreen, MD, Division of Infectious Diseases, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA


    L. Polgreen, None

    B. Riedle, None

    J. Cavanaugh, None

    M. Schroeder, None

    P. M. Polgreen, None

    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.